MDMichael Dreher

Michael Dreher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Dreher has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Spot Check Analysis of Gas Exchange: Invasive versus Noninvasive Methods

    by Emelie Ekkernkamp, Lena Welte, Claudia Schmoor, Sophie Emilia Huttmann, Michael Dreher, Wolfram Windisch, Jan Hendrik Storre

    Background: Correct measurement of PO2 and PCO2 is essential to establish appropriate therapy such as long-term oxygen therapy (LTOT) in patients suffering from respiratory failure. Objectives: We aimed to compare common invasive and noninvasive methods for assessing blood gas components for spot check analysis. Methods: Arterial (PaO2, PaCO2) and capillary blood gas (PCBGO2, PCBGCO2) measurements were taken consecutively in a randomized order and were compared with noninvasive measurements obtained from the transcutaneous monitoring of PO2 and PCO2 (PtcO2, PtcCO2, sensor-temperature 44°C). Capillary samples were taken from both arterialized earlobes, where samples of right earlobes were defined as a reference value. Pain assessment of all measurements was evaluated by each subject using the 100-mm visual analogue scale. Results: 83 patients and 17 healthy subjects were included. The mean difference between PaO2 and PtcO2 was 11.9 ± 15.0 mm Hg, with lower limits of agreement (LLA) of -17.4 mm Hg (95% confidence interval (CI) -22.5 to -12.3 mm Hg), and upper limits of agreement (ULA) of 41.1 mm Hg (95% CI 36.0-46.2 mm Hg). The comparison of PaO2 with PCBGO2 showed a mean difference of 5.6 ± 7.2 mm Hg (LLA -11.0; ULA 19.6 mm Hg). The mean difference between PaCO2 and PtcCO2 was 1.1 ± 4.9 mm Hg (LLA -8.6; ULA 10.8 mm Hg) and that between PaCO2 and PCBGCO2 was 0.7 ± 2.0 mm Hg (LLA -3.3; ULA 4.8 mm Hg). The analysis of capillary blood gases (36.2 ± 22.3 mm) was rated as more painful than the analysis of arterial blood gases (26.1 ± 20.6 mm), while transcutaneous measurement was rated as the least painful method (1.9 ± 7.4 mm; all p < 0.0001). Conclusions: The comparison of different methods for blood gas measurements showed substantial differences between capillary and arterial PO2 and between transcutaneous and arterial PO2. Therefore, arterial PO2 analysis is the essential method evaluating indication for LTOT. Nevertheless, comparative analysis further indicated capillary PCO2 as an adequate surrogate for arterial PCO2.


  • Impact of obesity on exercise performance and pulmonary rehabilitation

    by Michael Dreher, Hans‐Joachim Kabitz

    While the impact of obesity on respiratory function has been extensively studied, and several definitive conclusions have emerged, its impact on exercise performance is complex, with the available data sometimes providing contradictory or inconclusive information.Based on the literature discussed, it appears that resting alterations in lung volumes and gas exchange become attenuated during exercise in the obese, while oxygen cost of breathing and dyspnoea are increased. Respiratory muscle function also seems to be impaired, such that inspiratory muscle strength is reduced and respiratory drive is increased. Furthermore, while there is no reduction in the absolute values of maximal oxygen uptake compared with normal‐weight subjects, oxygen uptake at a given workload is increased and maximal workload is reduced in the obese, caused by increases in body mass and/or basal metabolic rate. To date, obesity has not been listed as an indication for pulmonary rehabilitation (PR), hence the reason why conclusive data on the impact of obesity per se on PR are lacking. The majority of evidence discussed is based on comparative data from obese versus normal‐weight patients, with respiratory disorders currently established as indications for PR. The best evidence currently available regarding the impact of obesity on PR is for patients with chronic obstructive pulmonary disease (COPD); here, it appears that obesity per se has no negative impact on PR. Otherwise, there are no conclusive data on the impact of obesity on PR in respiratory disorders other than COPD, and this remains to be investigated in the future.


  • Noninvasive Ventilation in COPD

    by Michael Dreher, Emelie Ekkernkamp, Stephan Walterspacher, David Walker, Claudia Schmoor, Jan H. Storre, Wolfram Windisch


  • Außerklinische Beatmung

    by M. Dreher, W. Windisch


  • Open Access

    Sedation during Flexible Bronchoscopy in Patients with Pre-Existing Respiratory Failure: Midazolam versus Midazolam plus Alfentanil

    by Michael Dreher, Emelie Ekkernkamp, Jan Hendrik Storre, Hans-Joachim Kabitz, Wolfram Windisch

    Background: The use of sedation during flexible bronchoscopy (FB) is undisputed; however, the combination of benzodiazepines and opiates, although reasonable, is suggested to cause hypoventilation, particularly in patients with pre-existing respiratory failure. Objectives: To assess respiratory function during FB. Methods: Transcutaneous PCO2 (PtcCO2), oxygen saturation, patients’ tolerance, time after FB until recovery and application of drug dosage were assessed in patients receiving either midazolam with alfentanil (n = 15) or midazolam alone (n = 15) for sedation for FB. Results: There were no differences in PtcCO2 values during FB between the two groups (all p > 0.05). However, PtcCO2 significantly increased over time in both groups (both p < 0.001; RM-ANOVA on ranks). Minimum oxygen saturation (SaO2) [89 (interquartile range 79.8/92.8) vs. 86 (interquartile range 82.3/87.8)%; p = 0.46] and the duration until recovery, i.e., achieving an ALDRETE score of ≧9 [30 (interquartile range 10/90) vs. 10 (interquartile range 10/105) min; p = 0.68] were comparable for monosedation and combined sedation, respectively. The total amount of midazolam [4.0 (interquartile range 4.0/4.0) vs. 2.0 (interquartile range 2.0/2.0) mg; p < 0.001] was lower in patients receiving combined sedation. Significantly lower scores for pain and asphyxia, and a clear tendency to less nausea and cough were reported by patients receiving combined sedation. Conclusions: Combined sedation during FB produced a comparable degree of desaturation and hypoventilation, and is associated with a comparable time to full recovery compared to monosedation in patients with pre-existing respiratory failure. Importantly, FB using combined sedation is better tolerated by patients despite only 50% midazolam consumption.


  • Open Access

    Proportional Assist Ventilation Improves Exercise Capacity in Patients with Obesity

    by Michael Dreher, Hans-Joachim Kabitz, Verena Burgardt, Stephan Walterspacher, Wolfram Windisch

    Background: Exercise capacity is reduced in obese patients due to disadvantageous respiratory mechanics that lead to dyspnea. Proportional assist ventilation (PAV) has the potential to unload resistive and elastic burdens of the ventilatory system. Objectives: The present study aimed to test if PAV can increase endurance and reduce exercise-related dyspnea in obese patients. Methods: Two symptom-limited exercise tests were performed at 75% of V·O2max: (1) without PAV and (2) with PAV. Exercise endurance, blood gases, dyspnea and limb discomfort (Borg scale) were assessed. Responders to PAV were defined as those increasing their exercise duration by more than 20%. Results: Eighteen male obese patients (body mass index 35 ± 5 kg/m2) were investigated. Overall, PAV increased exercise duration by 13% (p = 0.037) and improved exercise-induced dyspnea (p = 0.004). In responders (n = 10), PAV increased the exercise duration by 31% from 721 ± 300 to 1,041 ± 454 s (p < 0.001) and reduced dyspnea (p = 0.004) as well as limb discomfort (p = 0.016). Following stepwise multiple linear regression analysis, prolonged exercise time with PAV can only be predicted from total lung capacity (p = 0.02), considering total lung capacity, V·O2max and body mass index. Conclusions: PAV applied during exercise led to an overall prolongation in exercise endurance and a reduction in dyspnea in obese patients. There was a broad spectrum of response to PAV, with more than 50% of patients increasing their exercise endurance by a mean of 31%. Therefore, PAV might serve as a novel treatment option to enhance exercise capacity in a subgroup of obese patients in rehabilitation programs.


  • Open Access

    High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD

    by Wolfram Windisch, Moritz Haenel, Jan H Storre, Michael Dreher

    Background: The objective of the present analysis is to describe the outcomes of high-intensity non-invasive positive pressure ventilation (NPPV) aimed at maximally decreasing PaCO2 as an alternative to conventional NPPV with lower ventilator settings in stable hypercapnic COPD patients.


  • Preserving Oxygenation during Walking in Severe Chronic Obstructive Pulmonary Disease: Noninvasive Ventilation versus Oxygen Therapy

    by M. Dreher, E. Doncheva, A. Schwoerer, S. Walterspacher, F. Sonntag, H.J. Kabitz, W. Windisch

    Background: Physical activity is known to cause significant deoxygenation in patients with severe chronic obstructive pulmonary disease (COPD). Although noninvasive positive pressure ventilation (NPPV) has been shown to improve oxygenation and physical activity in these patients, no practical approach for the application of NPPV during walking has yet been established. Objective: To elucidate the most effective approach to preserving oxygenation during walking in patients with severe COPD receiving long-term NPPV. Methods: Three 12-min walking tests were performed in a randomized cross-over design on 3 consecutive days, comparing the usual and double dosages of oxygen versus NPPV plus the usual dosage of oxygen. The ventilator and oxygen tank were placed in a backpack. Results: Eleven patients (FEV1 26 ± 9% predicted) completed the study, while 8 patients refused to walk with NPPV, due to the weight of the ventilatory device (7.3 kg with NPPV vs. 3.1 kg without). PaO2 changes during walking differed [p = 0.01, repeated-measures (RM)-ANOVA], whereas dyspnea was unchanged. The difference in PaO2 change was 14.0 ± 16.6 mm Hg (unadjusted p = 0.0036, critical level = 0.017, RM-ANOVA) in favor of NPPV compared to the usual dosage of oxygen. Changes in FEV1, tidal volume and inspiratory impedance were in favor of NPPV-aided exercise (all p < 0.05, RM-ANOVA). Walking distance was reduced under NPPV (555 ± 227 m) compared to the usual (619 ± 210 m) and double (622 ± 215 m) dosages of oxygen (p = 0.024, RM-ANOVA). Conclusions: NPPV plus supplemental oxygen, but not oxygen alone, preserves oxygenation during walking in patients with severe COPD. However, dyspnea and walking distance were not improved due to the burden of carrying the heavy ventilatory equipment in a backpack.


  • Open Access

    Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report

    by Hinrich C Bremer, Wolfgang Kreisel, Kai Roecker, Michael Dreher, Daniel Koenig, Anna Katharina Kurz-Schmieg, Hubert E Blum, Martin Roessle, Peter Deibert

    Background: Portopulmonary hypertension (PPHTN) is a severe complication in liver cirrhosis. PDE5 inhibitors lower pulmonary arterial pressure (PAP) in PPHTN. However, their effect on portal hypertension has not yet been investigated. Case presentation: A 55 year old male patient presented with PPHTN and alcoholic liver cirrhosis. 10 mg of Tadalafil, a PDE5 inhibitor with a long half-life, was administered orally under continuous monitoring of pulmonary and portal hemodynamics. For maintenance therapy the patient received Sildenafil 20 mg bid. Tadalafil lowered mean PAP from 45 to 39 mmHg within 60 minutes. Cardiac output (CO) increased from 6.8 to 7.9 l/min. Central venous pressure (CVP) remained stable at 3 mmHg. Systolic and diastolic blood pressure was lowered from 167/89 to 159/86 mmHg. Pulse rate increased from 75 to 87 per min. Wedged hepatic vein pressure (WHVP) decreased from 21 to 18 mm Hg, hepatovenous pressure gradient (HVPG) decreased from 10 to 7 mmHg. Hemodynamic monitoring after 6 months of Sildenafil therapy revealed a sustained lowering of mean PAP. HVPG remained constant at 10 mmHg. Cardiac and pulmonary performance had further improved. Conclusion: This case report shows for the first time, that phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension.